Skip to content
BIIB·Nasdaq·US

Biogen

Biogen is a biotechnology company focused on therapies for neurological and autoimmune diseases. It develops, manufactures, and commercializes prescription medicines and also participates in research partnerships and licensing arrangements to extend its pipeline.

Recent Activity

Updated Oct 17, 2026
–Biogen is a backer of Estuary Biotherapeutics, a California-based genetic medicines developer that officially launched on Friday.

Past updates are part of the Pro plan.

Thematic Position

BIIB

Relationship Groups

Suppliers5
Customers1
Partners11
Licensing6
Competitors19

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

12 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

drug pricing regulationexecutive order
U.S. Executive Order proposes MFN drug pricing policy tying U.S. prices to international levels
SEC 10-QJul 29, 2026

The full regulatory passage is part of the Pro plan.

40 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

1 customer · Named major customers are part of the Pro plan.